A Randomised, Double-Blind, Active Placebo-Controlled, Parallel Groups, Dose-Response Study of Scopolamine Hydrobromide (4–6 Μg/Kg) in Patients With Major Depressive Disorder
Trials - United Kingdom
doi 10.1186/s13063-020-4089-6
Full Text
Open PDFAbstract
Available in full text
Date
February 10, 2020
Authors
Publisher
Springer Science and Business Media LLC